GLP-1s can cost more than $1,000 a month. Here’s how employers keep access without the open-ended bill
Upgrades Health · October 14, 2026 · 5 minute read
Most employers we talk to are stuck between two bad options on GLP-1s: cover them and watch an open-ended line item grow, or drop them and tell employees who need help that they are on their own. There is a third option, and it starts with putting a ceiling on the cost.
Why the bill keeps growing
The list price is the first problem. Novo Nordisk lists Wegovy at $1,349.02 for a monthly package, and Eli Lilly lists Zepbound at up to $1,086.37 per fill. A March 2026 WEX analysis puts the cost of GLP-1 coverage above $1,000 per member per month, citing Capital Blue Cross.
The second problem is volume. WEX, citing Truveta, reports that GLP-1s made up more than 7% of all prescriptions by December 2025. And the underlying need is not shrinking: the CDC reports that 40.3% of U.S. adults had obesity in 2021 to 2023, and research cited by the CDC puts the extra medical cost at $1,861 per adult with obesity every year.
Put those together and a traditional pharmacy benefit does exactly what it was built to do: pay whatever the claims add up to. That is the part employers cannot budget for.
The fix is structure, not exclusion
The WEX piece makes a point we agree with: the answer is to separate GLP-1 spending from the open-ended medical and pharmacy plan and fund it in a defined, capped way. Their example uses a health reimbursement arrangement with a set monthly or quarterly amount per eligible employee. The principles carry over to any program:
- Set the spend in advance. A fixed amount per enrolled employee, not whatever the claims total.
- Define who qualifies. Clear eligibility, applied the same way for everyone.
- Keep it simple for employees. If enrolling is confusing, people either give up or call HR.
- Say what is covered, plainly. Trust drops fast when employees discover limits after they start.
Where 
fits
Upgrades Health is built around that same idea of a ceiling, with care attached:
- No service fee. There is no platform, admin or setup charge. You pay only for the medication you choose to cover.
- One monthly price per member, quoted for your company. It stays the same at every dose, so the number you budget is the number you spend.
- You set the contribution. Cover it fully, split it, or offer access with no company spend at all.
- A licensed U.S. clinician on every prescription. Members are evaluated before anything is prescribed and supported through dose changes and side effects.
- U.S.-based medication. Compounded semaglutide and tirzepatide are prepared for each member by state-licensed U.S. pharmacies. Compounded medications are not FDA-approved.
- Program-level reporting only. HR never sees who enrolls or what anyone is prescribed.
Run your own numbers
Every workforce is different. Our ROI calculator shows what obesity already costs a plan your size and what brand-name list prices would add, and the pitch PDF builder turns it into a two-page proposal with your logo for your CFO or broker. When you are ready, book a call and we will quote a monthly price for your company.
Sources: WEX, “A smarter way for employers to offer GLP-1 access, with built-in cost control” (March 2026), citing Capital Blue Cross and Truveta; Novo Nordisk NovoCare and Eli Lilly pricing pages (2026); CDC NCHS Data Brief 508 (2024); Ward et al., PLoS ONE 2021 (2019 dollars). Estimates and prices vary by plan; this article is not a guarantee of savings.
